Plus Therapeutics, Inc. (PSTV)

Market Cap	6.43M
Revenue (ttm)	5.73M
Net Income (ttm)	-12.89M
Shares Out	5.90M
EPS (ttm)	-3.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	48,793
Open	1.010
Previous Close	0.990
Day's Range	0.971 - 1.110
52-Week Range	0.930 - 2.670
Beta	0.68
Analysts	Strong Buy
Price Target	13.50 (+1,138.53%)
Earnings Date	Nov 14, 2024

About PSTV

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 20
• Stock Exchange: NASDAQ
• Ticker Symbol: PSTV
• Website: https://plustherapeutics.com

Financial Performance

In 2023, Plus Therapeutics's revenue was $4.91 million, an increase of 2093.30% compared to the previous year's $224,000. Losses were -$13.32 million, -34.32% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for PSTV stock is "Strong Buy." The 12-month stock price forecast is $13.5, which is an increase of 1,138.53% from the latest price.

Price Target

$13.5

(1,138.53% upside)

Analyst Consensus: Strong Buy